The John McNicholas Pediatric Brain Tumor Foundation announced it has presented its first-ever High Grade Glioma Scholar Award, to Dr. Alexander Stegh of the Feinberg School of Medicine at Northwestern University. The award, valued at approximately $200,000, provides funding for physician scientist research on pediatric brain tumors with a focus on high grade gliomas, which are the deadliest and most common form of pediatric brain tumors.
The scholarship will help to fund Dr. Stegh’s groundbreaking research which studies how to overcome the blood brain barrier, which prevents many life-saving drugs from crossing into the brain. Dr. Stegh will be evaluating the effectiveness of a new compound called gold nanoparticles, and how these particles can bypass the blood brain barrier and directly enter a brain tumor for treatment. Dr. Stegh will also study how gold nanoparticles can be specifically designed to target two known genetic mutations for which there are no currently available drugs. His research will ultimately determine whether nanoparticles can inhibit the progression pediatric high grade gliomas.
HIGH GRADE GLIOMA SCHOLAR AWARD
The John McNicholas Pediatric Brain Tumor Foundation supports physician scientists conducting patient-oriented research on pediatric brain tumors with a focus on high-grade gliomas. The goal is to enhance research in high-grade gliomas in search of enhanced basic understanding, novel therapies, prognostic variables, and breakthrough treatment strategies, particularly in a younger patient population.
The John McNicholas Pediatric Brain Tumor Foundation anticipates funding one Scholar per year. Each total award is limited to $200,000 in direct costs over two years. Indirect costs will not be supported by this mechanism.